These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 20656333)

  • 21. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemostatic proteins gene polymorphisms in patients with unusual vein thrombosis and Ph-myeloproliferative disorders.
    Randi ML; Lombardi AM; Scapin M; Tezza F; Scandellari R; Ruzzon E; Duner E; Fabris F
    Thromb Haemost; 2007 Sep; 98(3):702-4. PubMed ID: 17849070
    [No Abstract]   [Full Text] [Related]  

  • 23. Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis.
    Mignon I; Grand F; Boyer F; Hunault-Berger M; Hamel JF; Macchi L
    Am J Hematol; 2013 Dec; 88(12):1007-11. PubMed ID: 23873831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state.
    Pereira J; Alfaro G; Goycoolea M; Quiroga T; Ocqueteau M; Massardo L; Pérez C; Sáez C; Panes O; Matus V; Mezzano D
    Thromb Haemost; 2006 Jan; 95(1):94-9. PubMed ID: 16543967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
    Baccouche H; Ben Jemaa M; Chakroun A; Chadi S; Mahjoub S; Sfar I; Gorgi Y; Ben Romdhane N
    Int J Lab Hematol; 2017 Oct; 39(5):502-507. PubMed ID: 28497580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global coagulation in myeloproliferative neoplasms.
    Tripodi A; Chantarangkul V; Gianniello F; Clerici M; Lemma L; Padovan L; Gatti L; Mannucci PM; Peyvandi F
    Ann Hematol; 2013 Dec; 92(12):1633-9. PubMed ID: 23820940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.
    Haubold K; Rink M; Spath B; Friedrich M; Chun FK; Marx G; Amirkhosravi A; Francis JL; Bokemeyer C; Eifrig B; Langer F
    Thromb Haemost; 2009 Jun; 101(6):1147-55. PubMed ID: 19492160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.
    Cella G; Marchetti M; Vianello F; Panova-Noeva M; Vignoli A; Russo L; Barbui T; Falanga A
    Thromb Haemost; 2010 Jul; 104(1):151-6. PubMed ID: 20431848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
    Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
    Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombin Generation Testing in Patients with Myelofibrosis.
    Palova M; Slavik L; Hlusi A; Szotkowski T; Ulehlova J; Divoka M; Navratilova J; Papajik T
    Clin Lab; 2018 Sep; 64(9):1373-1383. PubMed ID: 30274004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
    Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M
    Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
    Falanga A; Marchetti M; Barbui T; Smith CW
    Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
    Ricksten A; Palmqvist L; Johansson P; Andreasson B
    Haematologica; 2008 Aug; 93(8):1260-1. PubMed ID: 18519514
    [No Abstract]   [Full Text] [Related]  

  • 37. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events.
    Alvarez-Larrán A; Bellosillo B; Pereira A; Kerguelen A; Hernández-Boluda JC; Martínez-Avilés L; Fernández-Rodríguez C; Gómez M; Lombardía L; Angona A; Ancochea A; Senín A; Longarón R; Navarro B; Collado M; Besses C
    Am J Hematol; 2014 May; 89(5):517-23. PubMed ID: 24458835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study.
    Gisslinger H; Müllner M; Pabinger I; Heis-Vahidi-Fard N; Gisslinger B; Brichta A; Bachleitner-Hofmann T; Mannhalter C
    Haematologica; 2005 Mar; 90(3):408-10. PubMed ID: 15749677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.